SPARC and neuroblastoma: Recently, two antiangiogenic SPARC peptides have recently been shown to inhibit the progression of neuroblastoma tumors both in vitro and in vivo, heralding an optimistic future for SPARC as an antivascular cancer therapeutic [79].